🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Anderson-Fabry Disease

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease NCT06328608Phase 2, Phase 312 sites📍 Phoenix📍 Atlanta📍 Iowa City Chiesi Farmaceutici S.p.A. · Tests: PRX-102 1 mg/kg every two weeks Taiwan Associated Genetic and Nongenetic Small Vessel Disease NCT05473637n/a1 site📍 Taipei National Taiwan University Hospital · Tests: MRI Fabry Cardiomyopathy: Identification of Early Myocardial Structural and Tissue Abnormalities Using Multiparametric MRI NCT04856059NA1 site📍 Toronto University Health Network, Toronto · Tests: Cardiac MRI, ECG/Holter and Blood Biomarkers A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease NCT06858397Phase 1, Phase 210 sites📍 Los Angeles📍 Kansas City📍 Minneapolis GC Biopharma Corp · Tests: HM15421/GC1134A A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease NCT07187440n/a18 sites📍 Hefei📍 Beijing📍 Beijing Takeda · Tests: No intervention A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients NCT06663358n/a10 sites📍 Birmingham📍 Atlanta📍 Chicago Chiesi Farmaceutici S.p.A. · Tests: Pegunigalsidase-alfa Canadian Fabry Disease Initiative (CFDI) National Registry NCT00455104n/a5 sites📍 Calgary📍 Vancouver📍 Halifax Canadian Fabry Research Consortium · Tests: No intervention Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease NCT06539624NA2 sites📍 Shanghai📍 Hangzhou The Children's Hospital of Zhejiang University School of Me… · Tests: EXG110 injection Cardiovascular Multimodality Imaging Study NCT06610019n/a1 site📍 The Bronx Montefiore Medical Center Evaluation of the Safety, Tolerability and Efficacy of a Gene Therapy Drug for the Treatment of Pediatric Fabry Disease NCT06207552EARLY Phase 11 site📍 Shanghai Children's Hospital of Fudan University · Tests: BBM-F101 injection A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding NCT04252066n/a1 site📍 Philadelphia Amicus Therapeutics · Tests: migalastat Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding NCT06941025n/a5 sites📍 Washington D.C.📍 Berlin📍 Rome Chiesi Farmaceutici S.p.A. · Tests: Not applicable- observational study Evaluation of HEArt invoLvement in Patients With FABRY Disease NCT03362164n/a1 site📍 Würzburg Wuerzburg University Hospital Fabry Disease Registry & Pregnancy Sub-registry NCT00196742n/a284 sites📍 Birmingham📍 Birmingham📍 Phoenix Genzyme, a Sanofi Company Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study. NCT06607471n/a1 site📍 Milan Scientific Institute San Raffaele · Tests: Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation, Suppor… Long Duration Holter ECG in Fabry Disease NCT04440254NA1 site📍 Paris Institut National de la Santé Et de la Recherche Médicale, … · Tests: Implantation (subcutaneous) of a marketed miniaturized Holter ECG recording device A Study of Patients With Fabry Disease (US Specific) NCT06906367n/a8 sites📍 Birmingham📍 Little Rock📍 Atlanta Amicus Therapeutics · Tests: migalastat HCl, ERT Anderson-Fabry Disease Fitness Improvement Training NCT07495410NA1 site📍 Prague General University Hospital, Prague · Tests: Physiotherapy exercise programe Functional Capacity in Anderson-Fabry Disease Patients NCT06884358n/a5 sites📍 Brescia📍 Milan📍 San Donato Milanese IRCCS Policlinico S. Donato Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation NCT06813443n/a3 sites📍 Bologna📍 Roma📍 Florence IRCCS Azienda Ospedaliero-Universitaria di Bologna Italian Anderson Fabry Disease Cardiovascular Registry NCT06806813n/a54 sites📍 Chieti📍 Potenza📍 Caserta IRCCS Azienda Ospedaliero-Universitaria di Bologna Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease NCT05710692Phase 2, Phase 310 sites📍 Chikushino-shi📍 Sendai📍 Nishihara Chiesi Farmaceutici S.p.A. · Tests: PRX-102 1 mg/kg every 2 weeks, PRX-102 2 mg/kg every 4 weeks Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR Study NCT07235709n/a1 site📍 Seoul Yonsei University Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE) NCT07575347n/a1 site📍 Bucharest Stefan Lujinschi · Tests: Observational assessment A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants NCT06904261Phase 312 sites📍 Atlanta📍 Minneapolis📍 Charlotte Amicus Therapeutics · Tests: Migalastat HCl 20 mg National Registry of Rare Kidney Diseases NCT06065852n/a1 site📍 Bristol UK Kidney Association the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease NCT06776419n/a1 site📍 Copenhagen Caroline Michaela Kistorp · Tests: Cardiac Magnetic Ressonance Imaging, 82Rubidium-positron emission tomography and computer-tomography 4D-310 in Adults With Fabry Disease and Cardiac Involvement NCT05629559Phase 1, Phase 24 sites📍 Melbourne📍 Perth📍 Westmead 4D Molecular Therapeutics · Tests: 4D-310 Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease NCT06325488n/a1 site📍 Copenhagen Caroline Michaela Kistorp Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a Real-world Setting NCT07109375n/a7 sites📍 Arezzo📍 Bari📍 Bologna Chiesi Italia · Tests: pegunigalsidase alfa
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy